Diabetic Autonomic Neuropathy

Categories: Neuronal diseases

Aliases & Classifications for Diabetic Autonomic Neuropathy

MalaCards integrated aliases for Diabetic Autonomic Neuropathy:

Name: Diabetic Autonomic Neuropathy 12 54 15 70
Diabetic Neuropathies 44 70


External Ids:

Disease Ontology 12 DOID:11503
MeSH 44 D003929
NCIt 50 C27068
SNOMED-CT 67 50620007
UMLS 70 C0011882 C0271686

Summaries for Diabetic Autonomic Neuropathy

MalaCards based summary : Diabetic Autonomic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and neuropathy, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Autonomic Neuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are p70S6K Signaling and Peptide hormone metabolism. The drugs Bromocriptine and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, skin and kidney.

Related Diseases for Diabetic Autonomic Neuropathy

Diseases related to Diabetic Autonomic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 233)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.1 INS EPO AKR1B1
2 neuropathy 31.1 NTF3 NGF INS EPO AKR1B1 ACE
3 gastroparesis 30.7 MLNR MLN GAST
4 iritis 30.5 EPO ACE
5 pure autonomic failure 30.4 REN EPO ACE
6 silent myocardial infarction 30.4 INS ACE
7 autonomic neuropathy 30.3 PPY NTF3 NGF MLN INS GCG
8 algoneurodystrophy 30.3 NGF INS
9 polyneuropathy 30.3 NGF INS AKR1B1 ACE
10 peptic esophagitis 30.2 MLN GAST
11 neurogenic arthropathy 30.1 NGF INS
12 duodenal ulcer 30.1 MLN INS GAST
13 sensory peripheral neuropathy 30.0 NTF3 NGF AKR1B1
14 microvascular complications of diabetes 5 29.9 INS AKR1B1 ACE
15 nerve compression syndrome 29.9 NGF INS
16 diabetic polyneuropathy 29.9 NTF3 NGF INS AKR1B1
17 type 1 diabetes mellitus 29.9 REN INS GCG AKR1B1 ACE
18 diarrhea 29.8 SI REN MLN GAST
19 peripheral vascular disease 29.8 GAST EPO ACE
20 peripheral nervous system disease 29.8 NTF3 NGF INS GCG EPO AKR1B1
21 sexual disorder 29.7 REN INS ACE
22 hypertension, diastolic 29.7 REN ACE
23 glucose intolerance 29.7 INS GCG ACE
24 microvascular complications of diabetes 3 29.6 REN INS AKR1B1 ACE
25 vascular disease 29.5 REN INS EPO ACE
26 sleep apnea 29.5 REN INS EPO ACE
27 proteinuria, chronic benign 29.5 REN INS ACE
28 acute cystitis 29.5 REN INS ACE
29 pulmonary edema 29.5 REN EPO ACE
30 diabetic neuropathy 29.4 REN NTF3 NGF INS EPO AKR1B1
31 constipation 29.4 NTF3 MLNR MLN INS GCG GAST
32 end stage renal disease 29.3 REN INS EPO ACE
33 kidney disease 29.1 REN INS EPO AKR1B1 ACE
34 pheochromocytoma 28.9 REN NGF MLN EPO ACE
35 diabetes mellitus 28.7 REN MLN INS GCG GAST EPO
36 type 2 diabetes mellitus 28.3 REN PPY INS GCG GAST EPO
37 autonomic dysfunction 10.6
38 hypoglycemia 10.6
39 cardiac conduction defect 10.4
40 resting heart rate, variation in 10.3
41 impotence 10.3
42 splenic flexure cancer 10.3 INS GCG
43 transient refractive change 10.3 INS AKR1B1
44 acute insulin response 10.3 INS GCG
45 neuroaxonal dystrophy 10.3
46 functional colonic disease 10.3 MLNR MLN
47 rumination disorder 10.3 MLNR MLN
48 pylorospasm 10.3 MLNR MLN
49 colonic pseudo-obstruction 10.3 MLNR MLN
50 paralytic ileus 10.3 MLN INS

Graphical network of the top 20 diseases related to Diabetic Autonomic Neuropathy:

Diseases related to Diabetic Autonomic Neuropathy

Symptoms & Phenotypes for Diabetic Autonomic Neuropathy

UMLS symptoms related to Diabetic Autonomic Neuropathy:

sciatica; neuralgia

Drugs & Therapeutics for Diabetic Autonomic Neuropathy

Drugs for Diabetic Autonomic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 255)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
tannic acid Approved Phase 4 1401-55-4
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Acetaminophen Approved Phase 4 103-90-2 1983
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
Sodium citrate Approved, Investigational Phase 4 68-04-2
Cetirizine Approved Phase 4 83881-51-0 2678
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Donepezil Approved Phase 4 120014-06-4 3152
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
22 Hormone Antagonists Phase 4
23 Dopamine agonists Phase 4
24 Antiparkinson Agents Phase 4
25 Vasodilator Agents Phase 4
26 Antimetabolites Phase 4
27 Angiotensin-Converting Enzyme Inhibitors Phase 4
28 Antihypertensive Agents Phase 4
29 HIV Protease Inhibitors Phase 4
protease inhibitors Phase 4
31 Hypoglycemic Agents Phase 4
32 Insulin, Globin Zinc Phase 4
33 insulin Phase 4
34 Alpha-lipoic Acid Phase 4
35 Thioctic Acid Phase 4
36 Antipyretics Phase 4
37 Hypolipidemic Agents Phase 4
38 Lipid Regulating Agents Phase 4
39 Calciferol Phase 4
40 Vitamin B 6 Phase 4
41 Sodium Channel Blockers Phase 4
42 Diuretics, Potassium Sparing Phase 4
43 Anticholesteremic Agents Phase 4
44 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
45 Sodium-Glucose Transporter 2 Inhibitors Phase 4
46 Anti-Allergic Agents Phase 4
47 Histamine Antagonists Phase 4
Histamine Phosphate Phase 4 51-74-1 65513
49 Histamine H1 Antagonists Phase 4
50 abobotulinumtoxinA Phase 4

Interventional clinical trials:

(show top 50) (show all 432)
# Name Status NCT ID Phase Drugs
1 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
2 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
3 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
4 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
5 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
6 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
7 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
8 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
9 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
10 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Completed NCT03271151 Phase 4 Cymbalta
11 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
12 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
13 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
14 A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
15 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
16 A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases Completed NCT01352767 Phase 4
17 The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients Completed NCT04238208 Phase 4 Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
18 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
19 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
20 The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
21 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
22 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
23 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
24 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
25 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
26 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
27 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
29 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
30 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
31 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
32 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
33 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
34 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
35 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
36 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
37 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
38 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
39 Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain. Completed NCT03047278 Phase 4 Gabapentin 300 mg;Cetirizine Hydrochloride 10 mg
40 Phase IV Open Non Comparative Trial to Evaluate Efficacy and Safety of Tegretol® in Diabetes Neuropathy Pain. Completed NCT01089855 Phase 4 Carbamazepine
41 Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM) Recruiting NCT04246619 Phase 4 Pregabalin;Duloxetine
42 Effect of High-Dose N-acetyl Cysteine (NAC) on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy (DPN) Not yet recruiting NCT04766450 Phase 4 Acetyl cysteine
43 Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy Terminated NCT00487981 Phase 4
44 Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy Terminated NCT00619983 Phase 4 donepezil;duloxetine;donepezil 2.5 mg and duloxetine 30mg;placebo;gabapentin
45 A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Terminated NCT02156336 Phase 4 Ranolazine;Placebo
46 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
47 A Randomized, Double-Blind, Placebo Controlled, Parallel Assignment, Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain Unknown status NCT01035281 Phase 3 Nabilone, flexible dosing
48 A Randomized, Sham-Controlled Clinical Study to Evaluate The Effect of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy Unknown status NCT00134524 Phase 3
49 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months. Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
50 Diabetic Neuropathic Pain Topical Treatment- Comparative Study Unknown status NCT00661063 Phase 3 ketamine;vehicle gel;ketamine + clonidine;clonidine gel 1%

Search NIH Clinical Center for Diabetic Autonomic Neuropathy

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Capsicum extract
Citalopram hydrobromide
Mexiletine Hydrochloride
Vitamin B 12

Cochrane evidence based reviews: diabetic neuropathies

Genetic Tests for Diabetic Autonomic Neuropathy

Anatomical Context for Diabetic Autonomic Neuropathy

MalaCards organs/tissues related to Diabetic Autonomic Neuropathy:

Spinal Cord, Skin, Kidney, Heart, Bone Marrow, Pancreas, Eye

Publications for Diabetic Autonomic Neuropathy

Articles related to Diabetic Autonomic Neuropathy:

(show top 50) (show all 1051)
# Title Authors PMID Year
Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. 54 61
11245210 2001
Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. 61 54
9647338 1998
Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. 61 54
18370475 1998
An investigation of antibodies to nerve growth factor in diabetic autonomic neuropathy. 54 61
8088110 1994
Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. 54 61
8299441 1993
Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor. 61 54
8482988 1993
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus. 54 61
2123430 1990
Impaired hypoxic ventilatory drive induced by diabetic autonomic neuropathy, a cause of misdiagnosed severe cardiac events: brief report of two cases. 61
33731006 2021
Glycated Hemoglobin (HbA1c) as a Biomarker for Diabetic Foot Peripheral Neuropathy. 61
33671807 2021
Diabetic neuropathies. 61
32589300 2021
Stem Cell Therapies for the Treatment of Diabetic Neuropathies: Future Perspectives. 61
32303173 2021
Is Perls Prussian Blue Stain for Hemosiderin a Useful Adjunct in the Diagnosis of Vasculitic Neuropathies? 61
33642286 2021
Study protocol for a multicentre, randomised, parallel group, sham-controlled clinical trial investigating the effect of transcutaneous vagal nerve stimulation on gastrointestinal symptoms in people with diabetes complicated with diabetic autonomic neuropathy: the DAN-VNS Study. 61
33408197 2021
Autonomic neuropathy and urologic complications in diabetes. 61
33197694 2020
Gastrointestinal autonomic neuropathy in diabetes. 61
32916479 2020
The Effect of Intradermal Botulinum Toxin a injections on painful diabetic polyneuropathy. 61
32961514 2020
The effectiveness of automatic pupillometry as a screening method to detect diabetic autonomic neuropathy. 61
32623631 2020
[Establishment and Validation of Animal Models of Peripheral Diabetic Neuropathies]. 61
33131522 2020
Diabetic autonomic neuropathy: a clinical update. 61
32936100 2020
Divergent pathologies and treatment options for diabetic neuropathies. 61
32661751 2020
Clinical spectrum and diagnosis of diabetic neuropathies. 61
32921007 2020
[Causes, spectrum, and treatment of the diabetic neuropathy]. 61
32647958 2020
Role of platelet-derived growth factor in type II diabetes mellitus and its complications. 61
32744067 2020
Assessment of cutaneous axon-reflex responses to evaluate functional integrity of autonomic small nerve fibers. 61
32125538 2020
Modeling Hypoxia-Induced Neuropathies Using a Fast and Scalable Human Motor Neuron Differentiation System. 61
32386561 2020
Expression study of candidate miRNAs and evaluation of their potential use as biomarkers of diabetic neuropathy. 61
32400192 2020
Spectrum of diabetic neuropathies. 61
32206478 2020
Clinical Impact of Atypical Chest Pain and Diabetes Mellitus in Patients with Acute Myocardial Infarction from Prospective KAMIR-NIH Registry. 61
32059609 2020
Autonomic Peripheral Neuropathy. 61
31996622 2020
Static and Dynamic Pupillary Responses in Patients with Different Stages of Diabetic Retinopathy. 61
33012908 2020
Diabetic autonomic neuropathy of the gastrointestinal tract. 61
32550939 2020
Cholecystomegaly: A Case Report and Review of the Literature. 61
32884849 2020
Clinical and neurophysiological spectrum of polyneuropathies in children. 61
32939748 2020
Increased arrhythmia susceptibility in type 2 diabetic mice related to dysregulation of ventricular sympathetic innervation. 61
31625779 2019
Commentary: Abnormal pupillary light reflexes - A sign of diabetic autonomic neuropathy. 61
31332118 2019
Commentary: Recognizing pupillary dysfunction in diabetic autonomic neuropathy. 61
31332119 2019
Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. 61
31456118 2019
Association of pupil responses with severity of erectile dysfunction in diabetes mellitus. 61
31332117 2019
Role of Inflammation in the Pathogenesis of Diabetic Peripheral Neuropathy. 61
31592273 2019
Omega-3 polyunsaturated fatty acids exert anti-oxidant effects through the nuclear factor (erythroid-derived 2)-related factor 2 pathway in immortalized mouse Schwann cells. 61
30216708 2019
Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. 61
30935671 2019
Diabetic neuropathies influence recovery from hip-fracture surgery in older persons with diabetes. 61
30738920 2019
Painful and Painless Diabetic Neuropathies: What Is the Difference? 61
31065863 2019
Uncoupling neurotrophic function from nociception of nerve growth factor: what can be learned from a rare human disease? 61
30632491 2019
Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy. 61
30568127 2019
Droxidopa for Hypotension of Different Etiologies: Two Case Reports. 61
30828233 2019
Diagnostic accuracy of composite autonomic symptom scale 31 (COMPASS-31) in early detection of autonomic dysfunction in type 2 diabetes mellitus. 61
31564941 2019
Early Alterations of Corneal Subbasal Plexus in Uncomplicated Type 1 Diabetes Patients. 61
31341662 2019
['Point of no return' in diabetic neuropathies: a dangerous delusion]. 61
31626177 2019
Involvement of P2Y12 receptor of stellate ganglion in diabetic cardiovascular autonomic neuropathy. 61
30084083 2018

Variations for Diabetic Autonomic Neuropathy

Expression for Diabetic Autonomic Neuropathy

Search GEO for disease gene expression data for Diabetic Autonomic Neuropathy.

Pathways for Diabetic Autonomic Neuropathy

Pathways related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways

GO Terms for Diabetic Autonomic Neuropathy

Cellular components related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 REN PPY NTF3 NGF MLN INS
2 extracellular space GO:0005615 9.36 REN PPY NTF3 NGF INS GCG
3 endosome lumen GO:0031904 9.16 NGF INS

Biological processes related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.8 PPY MLNR MLN INS GCG GAST
2 nerve development GO:0021675 9.4 NTF3 NGF
3 amyloid-beta metabolic process GO:0050435 9.37 REN ACE
4 nerve growth factor signaling pathway GO:0038180 9.26 NTF3 NGF
5 angiotensin maturation GO:0002003 9.16 REN ACE
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.13 NTF3 INS EPO
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 8.8 NTF3 NGF GCG

Molecular functions related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.56 REN NTF3 NGF GCG
2 insulin-like growth factor receptor binding GO:0005159 9.16 REN INS
3 hormone activity GO:0005179 9.1 PPY MLN INS GCG GAST EPO
4 nerve growth factor receptor binding GO:0005163 8.96 NTF3 NGF

Sources for Diabetic Autonomic Neuropathy

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....